Zomedica Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting third-quarter net revenue of $9,899 thousand and a net loss of $3,166 thousand.

Key Highlights

  • Quarterly revenue of $9,899 thousand for the three months ended September 30, 2026, up from $8,095 thousand in the same period of 2025, according to the filing.
  • Nine-month revenue of $28,210 thousand for the period ended September 30, 2026, compared with $21,559 thousand for the same period in 2025.
  • Quarterly net loss of $3,166 thousand for Q3 2026, compared with a net loss of $6,121 thousand in Q3 2025.
  • Nine-month net loss of $11,465 thousand for the period ended September 30, 2026, versus a net loss of $77,328 thousand in the same period of 2025, which included $55,833 thousand in impairment expense.
  • Total assets of $115,026 thousand as of September 30, 2026, down from $127,039 thousand at December 31, 2025.
  • Accumulated deficit of $311,238 thousand as of September 30, 2026, compared with $299,773 thousand at December 31, 2025.
  • 979,949,668 common shares issued and outstanding as of September 30, 2026 and November 4, 2026, unchanged from December 31, 2025.

Zomedica's Third-Quarter 2026 Financial Results: Revenue Growth and Narrowing Losses

According to the filing, Zomedica Corp. (OTCQB:ZOMDF) reported third-quarter 2026 net revenue of $9,899 thousand, an increase from $9,899 thousand -- compared with $8,095 thousand in Q3 2025. Gross profit for Q3 2026 was $6,044 thousand, up from $5,436 thousand a year earlier. Cost of revenue rose to $3,855 thousand from $2,659 thousand in the prior-year quarter. The company's loss from operations in Q3 2026 was $3,425 thousand, an improvement from a loss from operations of $6,606 thousand in Q3 2025.

For the nine months ended September 30, 2026, the registrant reported net revenue of $28,210 thousand against $21,559 thousand in the comparable 2025 period. The nine-month 2025 results included $55,833 thousand in impairment expense, which the filing shows was absent in the 2026 year-to-date period. Operating expenses in the nine months ended September 30, 2026 included general and administrative costs of $15,497 thousand, selling and marketing of $11,052 thousand, and research and development of $3,428 thousand, all lower than the corresponding 2025 figures of $18,324 thousand, $14,018 thousand, and $5,523 thousand, respectively.

The consolidated balance sheet as of September 30, 2026 showed total shareholders' equity of $104,282 thousand, down from $115,397 thousand at December 31, 2025, primarily reflecting the year-to-date net loss. Cash and cash equivalents stood at $7,281 thousand, with available-for-sale securities of $32,845 thousand. Total liabilities were $10,744 thousand. Loss per share for the nine months ended September 30, 2026 was $(0.01), basic and diluted, compared with $(0.08) for the same period in 2025.

What Was Disclosed

Zomedica Corp. disclosed its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026, covering revenue, expenses, net loss, balance sheet position, and shareholders' equity, with 979,949,668 common shares outstanding.